Pharma BD Deal Intelligence

Pfizer Inc. / Merck KGaA

2014 · Co-Development · $2.9B · Complete

The Street Said

Positive — critic reaction at announcement

Mixed — partial payoff, real shortfalls

CALLED IT — OFF BY 8

Full analysis, sources & comparables →

Pfizer partnered with Merck KGaA to co-develop and co-commercialize avelumab (anti-PD-L1) across multiple oncology indications in a deal worth up to $2.85B.

Key facts

Announced Nov 17, 2014
Closed Nov 17, 2014
Deal value $2.9B
Deal type Co-Development
Therapeutic area Oncology
Indications Merkel cell carcinoma, Urothelial carcinoma, Multiple solid tumors
Key assets avelumab (MSB-0010718C)
Mechanism Anti-PD-L1 monoclonal antibody

Related deals — scored

Deal	Year	Value	Outcome
Pfizer Inc. / Merck KGaA (this deal)	2014	$2.9B	55
Pfizer Inc. / BioNTech SE	2020	$748M	100
Pfizer Inc. / FoldRx Pharmaceuticals	2010	—	99
Pfizer Inc. / Medivation Inc.	2016	$14.0B	86
Pfizer Inc. / Wyeth	2009	$68.0B	86
Pfizer Inc. / Warner-Lambert Company	2000	$90.0B	83
Pfizer Inc. / Arvinas, Inc.	2021	$2.4B	77

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals

More: 2014 deals · Pfizer Inc. deals · Oncology deals